Auris Medical Holding AG (NASDAQ:EARS) shares saw unusually-strong trading volume on Thursday . Approximately 437,681 shares were traded during trading, an increase of 353% from the previous session’s volume of 96,678 shares.The stock last traded at $4.45 and had previously closed at $3.95.

A number of research firms have recently commented on EARS. Zacks Investment Research raised shares of Auris Medical Holding AG from a “hold” rating to a “buy” rating and set a $4.50 target price for the company in a report on Tuesday, July 12th. Jefferies Group reissued a “buy” rating on shares of Auris Medical Holding AG in a report on Friday, June 10th. Finally, Leerink Swann reissued a “buy” rating on shares of Auris Medical Holding AG in a report on Thursday, May 12th.

The company’s market capitalization is $158.60 million. The company has a 50-day moving average price of $4.01 and a 200-day moving average price of $3.96.

Auris Medical Holding AG (NASDAQ:EARS) last issued its earnings results on Wednesday, May 11th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by $0.04. During the same period last year, the firm earned ($0.28) earnings per share. Equities analysts forecast that Auris Medical Holding AG will post ($1.01) EPS for the current fiscal year.

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.